

## Preparation of factor VII concentrate using CNBr-activated Sepharose 4B immunoaffinity chromatography

Kamran Mousavi Hosseini<sup>1</sup>, Saleh Nasiri<sup>2</sup>

Received: 9 February 2014

Accepted: 18 November 2014

Published: 28 January 2015

### Abstract

**Background:** Factor VII concentrates are used in patients with congenital or acquired factor VII deficiency or treatment of hemophilia patients with inhibitors. In this research, immunoaffinity chromatography was used to purify factor VII from prothrombin complex (Prothrombin-Proconvertin-Stuart Factor-Antihemophilic Factor B or PPSB) which contains coagulation factors II, VII, IX and X. The aim of this study was to improve purity, safety and tolerability as a highly purified factor VII concentrate.

**Methods:** PPSB was prepared using DEAE-Sephadex and was used as the starting material for purification of coagulation factor VII. Prothrombin complex was treated by solvent/detergent at 24°C for 6 h with constant stirring. The mixture of PPSB in the PBS buffer was filtered and then chromatographed using CNBr-activated Sepharose 4B coupled with specific antibody. Factors II, IX, VII, X and VIIa were assayed on the fractions. Fractions of 48-50 were pooled and lyophilized as a factor VII concentrate. Agarose gel electrophoresis was performed and Tween 80 was measured in the factor VII concentrate.

**Results:** Specific activity of factor VII concentrate increased from 0.16 to 55.6 with a purification-fold of 347.5 and the amount of activated factor VII (FVIIa) was found higher than PPSB (4.4-fold). Results of electrophoresis on agarose gel indicated higher purity of Factor VII compared to PPSB; these finding revealed that factor VII migrated as alpha-2 proteins. In order to improve viral safety, solvent-detergent treatment was applied prior to further purification and nearly complete elimination of tween 80 (2 µg/ml).

**Conclusion:** It was concluded that immunoaffinity chromatography using CNBr-activated Sepharose 4B can be a suitable choice for large-scale production of factor VII concentrate with higher purity, safety and activated factor VII.

**Keywords:** Factor VII, Activated factor VII, chromatography, Sepharose.

**Cite this article as:** Mousavi Hosseini K, Nasiri S. Preparation of factor VII concentrate using CNBr-activated Sepharose 4B immunoaffinity chromatography. *Med J Islam Repub Iran* 2015 (28 January). Vol. 29: 170.

### Introduction

Human coagulation factor VII (FVII) is a glycoprotein with a molecular mass of 50 KDa. It is synthesized in the liver and circulates in the blood at a plasma concentration of 0.5 µg/ml (1). In 1972 Dike, Bidwell and Rizza reported the preparation and clinical use of a concentrate of factor VII as a by-product of the preparation of a therapeutic concentrate of factors II, IX and X by

adsorption on DEAE-Cellulose (2). In 1973, it was concluded that DEAE-Sephadex was more suitable than DEAE-Cellulose for routine large-scale production of the prothrombin complex (3). In 1980, batch adsorption on DEAE-Sepharose CL-6B followed by elution on a chromatographic column, concentrated factor VII about 25-fold without a need for further dialysis or concentration steps (4). In 2003,

1. Associate Professor, Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran. [mkmousavi@yahoo.com](mailto:mkmousavi@yahoo.com)

2. (Corresponding author) Assistant Professor, Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran. [salehnasiri2012@gmail.com](mailto:salehnasiri2012@gmail.com)

an activated Factor VII (FVIIa) concentrate, prepared from human plasma on a large scale became available for clinical use for haemophiliacs with antibodies against FVIII and FIX (5). The management of bleeding episodes in patients with inhibitors may require different therapeutic approaches, among which factor VIIa (6-10) and prothrombin complex concentrates (11,12) have been successfully used. FEI-BA (Factor Eight Inhibitor Bypassing Activity, Immuno, Vienna, Austria) is an activated prothrombin complex concentrate which has been widely used in the treatment of hemophilia patients with inhibitors (13). Factor VII concentrates are used in patients with congenital or acquired factor VII deficiency or treatment of hemophilia patients with inhibitors (4-6). It was shown that high levels of FVIIa in prothrombin complex concentrates containing factor VII, may contribute to the thrombogenic potential of these preparations (14), therefore purifying FVII from PPSB should improve its thrombogenicity. This study was planned to improve tolerance and safety in the treatment of patients with preparing highly purified factor VII from PPSB using immunoaffinity chromatography technique (15-18).

### Methods

One thousand mililiter of Fresh Frozen Plasma was thawed overnight at 4°C. Then it was centrifuged for 7 minutes at 4°C (5000 g). The obtained supernatant was treated with DEAE-Sephadex A50 (Pharmacia). First, it was washed by sodium citrate 0.01 M, pH 7.0, and sodium chloride 0.2 M; followed by eluting with sodium citrate 0.01 M, pH 7.0, and sodium chloride 2.0 M. The eluted prothrombin complex was used as starting material for purification of coagulation factor VII. For the purpose of virus inactivation, the solvent/detergent method was applied. Prothrombin complex (50 ml) was treated with a mixture of 0.3% tri-(n-butyl) phosphate (TNBP) as solvent and 1% Tween 80 (detergent) at 24°C for 6 h with continuous

stirring.

Antiserum against human FVII (Assera factor VII, Stago) was further purified by ammonium sulphate 50%, after centrifugation dialyzed in coupling buffer (0.1 M NaHCO<sub>3</sub>, pH 8.3 containing 0.5 M NaCl) for overnight at 4°C.

Preparation of the CN Br-activated Sepharose 4B gel (2 g powder), coupling the ligand (Assera factor VII) with coupling buffer rotating overnight at 4°C, blocking excess remaining groups with Tris buffer (pH:8, 0.1 M) for 2 h and packing of the gel were performed. The ligand to be coupled, was dissolved in coupling buffer, 0.1M NaHCO<sub>3</sub> pH8.3 containing 0.5 M NaCl. Five ml of coupling solution was used per gram of CN Br-activated Sepharose 4B. The excess ligand was washed away with 5 volumes of coupling buffer (0.1M NaHCO<sub>3</sub> pH8.3). For blocking any remaining active groups, the medium was transferred into the 0.1 M Tris-HCl buffer, pH 8.0 for 2 hours.

The mixture of prepared prothrombin complex (50 ml) in the PBS buffer (pH: 7.4) was filtered (0.22 µ) and then chromatographed (Pharmacia LKB Fraction Collector 2210) on a column (K 9/15 Pharmacia) containing CNBr-activated Sepharose 4B coupled with specific antibody. Flow rate was adjusted to 0.75 ml/min. After washing step, elution was performed by glycine buffer (0.1 M, pH: 2.5) and FVII collected in collection phosphate buffer (1.0 M, pH:8) fractions.

Factors II, IX, VII, X and VIIa were assayed on the fractions by one stage clotting assay method using Stago kits. Fractions of 48-50 were pooled and lyophilized as a factor VII concentrate.

Agarose gel electrophoresis was performed using barbital buffer (pH: 8.6) at 220 V for 35 min with Ciba Corning equipment. Tween 80 was measured spectrophotometrically at 535 nm (19).

### Results

Elution pattern of FVII from PPSB is shown in Figure 1. In this pattern the major




Fig. 1. Elution pattern of factor VII from prothrombin complex concentrate (PPSB) using immunoaffinity chromatography.

peak of FVII (Fractions 48-50) and the minor peak of FIX (Fractions 46-51) has been shown; activity of other coagulation factors was lower. Other unabsorbed or unwanted proteins have been removed in breakthrough and other fractions.

Table 1 indicates the results of preparation of human coagulation FVII concentrate from PPSB by immunoaffinity chromatography step. Specific activity and purification-fold of FVII concentrate were 55.6 and 3971, respectively. Table 1 shows higher

purity of factor VII concentrate with lower coagulation activities of FII, FIX and FX during its preparation by immunoaffinity chromatography. The amount of activated factor VII (FVIIa) in FVII concentrate was higher than PPSB (4.4-fold) and the yield was 62%.

Table 2 shows the characteristics of coagulation factor VII and PPSB concentrates and confirms higher purity of factor VII concentrate.

The result of gel electrophoresis (Figure

Table 1. Results of preparation of coagulation factor VII concentrate from PPSB using immunoaffinity chromatography

Purification step	Total Protein FVII (mg)	Total Activity FVII (u)	Specific Activity FVII (u/mg)	Purification-fold*	Yield FVII (%)	FVIIa (u/dl)
PPSB	780	125	0.16	12.3	100	40
CNBr-activated Sepharose 4B	0.72	40	55.60	3971	62	175

\* Purification-fold was determined with regard to the specific activity of FVII in plasma (0.013).

Table 2. Characteristics of factor VII concentrate prepared by immunoaffinity chromatography.

	PPSB	Factor VII concentrate
Total protein (mg/dl)	1500	10
Factor II (u/dl)	2800	11
Factor IX (u/dl)	1800	12
Factor VII (u/dl)	250	555
Factor VIIa (u/dl)	40	175
Factor X (u/dl)	4800	9
Tween 80 (µg/ml)	-	2




Fig.2. Gel electrophoresis. Line 1, PPSB; Line 2, normal plasma; Line 3 highly purified FVII concentrate (fractions 48-50).

2) indicated that factor VII concentrate contained approximately 89% alpha-2 proteins, providing evidence of its improved purity as compared with PPSB which contains three major bands of alpha-1, alpha-2 and beta proteins. These findings revealed that factor IX migrated as alpha-1 and factor VII as alpha-2 proteins.

### Discussion

Apart from human plasma fractionation (20-26), the affinity chromatography is usually used as one of the final steps in the purification process of proteins. It combines advantages of time-saving and high capacity of selection and concentration of the target protein from a complex mixture of contaminating substances in a large sample volume (27). In this study we demonstrated that factor VII concentrate, essentially free of factors II, IX and X, can be further purified from prothrombin complex using immunoaffinity chromatography; and a virus inactivation step of solvent-detergent treatment could also be included. The specific activity of FVII in our

procedure was increased from 0.16 to 55.6 with purification-fold of 3975 and the yield was 62%. Activity of activated factor VII (FVIIa) in our purified concentrate and PPSB were 250% and 555% respectively. It indicates that factor VII concentrate similar to recombinant activated factor VII, may be used for treatment or prevention from bleeding in patients with factor IX inhibitors.

Viral inactivation and chromatographic methods are being used increasingly in the preparation of high purity plasma or blood component products and can also contribute to improve viral safety of the product (28-36). The potential ability of chromatography for eliminating viruses has been reviewed and up to more than 3-8 log<sub>10</sub> removal of various viruses used as models during some chromatographic steps (37-39). On the other hand, in this method lower pH: 2.5 conditions within the elution buffer may lead to further viral inactivation (40). It seems that application of both solvent-detergent method and immunoaffinity chromatography can increase viral safety efficiently in comparison with other purification methods.

It may be concluded that CNBr-activated Sepharose 4B immunoaffinity chromatography can be a suitable choice for large-scale production of factor VII concentrate with higher purity, safety tolerability, activated factor VII and may be used for treatment or prevention of bleeding in patients with factor IX inhibitors.

### References

1. Furie B, Furie BC. The molecular basis of blood coagulation. *Cell* 1988; 53: 505-518.
2. Dike GWR, Bidwell E, Rizza CR. The Preparation and Clinical Use of a New Concentrate Containing Factor IX, Prothrombin and Factor X and of a Separate Concentrate Containing Factor VII. *Br J Haematol* 1972; 22: 469-90.
3. Heystek J, Brummelhuis HG, Krunen HW. Contributions to the optimal use of human blood. II. The large-scale preparation of prothrombin complex. A comparison between two methods using the anion exchangers DEAE-cellulose DE 52 and DEAE-sephadex A-50. *Vox Sang* 1973; 25:



113-23.

4. Dike GW, Griffiths D, Bidwell E, et al. A factor VII concentrate for therapeutic use. *Br J Haematol* 1980; 45: 107-18.

5. Tomokiyo K, Yano H, Imamura M, et al. Large-scale production and properties of human plasma-derived activated factor VII concentrate. *Vox Sang* 2003; 84: 54-64.

6. Hedner U, Bjoern S, Bernvil SS, et al. Clinical experience with human plasma-derived factor VIIa in patients with hemophilia A and high titer inhibitors. *Haemostasis* 1989; 19: 335-43.

7. Lisman T, Adelmeijer J, Cauwenberghs S, et al. Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count. *J Thromb Haemost* 2005; 3: 742-51.

8. Kessler C. Haemostasis.com: clinical experiences in the investigational use of rFVIIa in the management of severe haemorrhage. *Br J Haematol* 2004; 127: 230.

9. Simpson E, Lin Y, Stanworth S, et al. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. *Cochrane Database Syst Rev* 2012; DOI:10.1002/14651858.CD005011.pub4.

10. Young G, McDaniel M, Nugent DJ. Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors. *Haemophilia* 2005; 11: 203-7.

11. Lusher JM, Shapiro SS, Palascak JE, et al. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. *N Engl J Med* 1980; 303: 421-5.

12. Yada K, Nogami K, Ogiwara K, et al. Activated prothrombin complex concentrate (APCC)-mediated activation of factor (F)VIII in mixtures of FVIII and APCC enhances hemostatic effectiveness. *J Thromb Haemost* 2013; DOI: 10.1111/jth.12197.

13. Negrier C, Goudemand J, Sultan Y, et al. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. *Thromb Haemost* 1997; 77: 1113-9.

14. Hellstern P, Beeck H, Fellhauer A, et al. Factor VII and activated-factor-VII content of prothrombin complex concentrates. *Vox Sang* 1997; 73: 155-61.

15. Kohler M. Thrombogenicity of prothrombin complex concentrates. *Thromb Res* 1999; 95: S13-7.

16. M. Köhler, P. Hellstern, E. Lechler, et al. Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates. *Thromb Haemost* 1988; 80: 399-402.

17. Sørensen B, Spahn DR, Innerhofer P, et al. Clinical review: Prothrombin complex concen-

trates--evaluation of safety and thrombogenicity. *Crit Care* 2011; 15: 201.

18. Baudoux E, Margraff U, Coenen A, et al. Hemovigilance: clinical tolerance of solvent-detergent treated plasma. *Vox Sang* 1998; 74 Suppl 1: 237-9.

19. Michalski C, Bal F, Burnouf T, Goudemand M. Large-scale production and properties of a solvent-detergent-treated factor IX concentrate from human plasma. *Vox Sang* 1988; 55: 202-10.

20. Mousavi Hosseini K, Nasiri S, Heidari M: Using ethanol and low temperature in separation of albumin from human plasma. *Journal of Zanzan University of Medical Sciences and Health Services* 2013;21(85):65-75.

21. Mousavi Hosseini K, Heidari M, Yari F. The preparation of albumin as a biological drug from human plasma by fiber filtration. *Tehran University Medical Journal* 2011; 69(5):283-288.

22. Mahmoodian Shooshtari, Mousavi Hosseini k. Evaluation of the plasma quality after filtration. *Daru* 2010;18(2),114-117.

23. Yari F, Mousavi Hosseini k. purification and polymerization method for bovine serum albumin preparation. *The Italian Journal of Biochemistry* 2007; 56(2),163-165.

24. Aghaei A, Pourfatollah A, Khorsand H, Rezvan H, Mousavi Hosseini K. Preparation of an intermediate product suitable for production of IVIg. *The Scientific Journal of Iranian Blood Transfusion Organization* 2006; 3(2),101-110.

25. Mousavi Hosseini K, Mojgan Pourmokhtar, Rasoul Dinarvand, Houri Rezvan, Mohammad Ali Jalili. Preparation of enriched immunoglobulin M and immunoglobulin A from human plasma. *Medical Journal of the Islamic Republic of Iran* 2004;17(4),315-318.

26. Sahebghadam Lotfi A, Dibi B, Mousavi Hosseini K, Mahmoodi M. Purification and isolation of  $\alpha_1$ -proteinase inhibitor and determination of some of its' physicochemical properties. *Modarres Journal of Medical Sciences* 2005;7(2),71-80.

27. Mousavi S, Rezvan H, Pourfatollah A, Mousavi Hosseini K. Improving purification of coagulation F IX using heparin affinity chromatography and its comparison with ion exchange chromatography. *The Scientific Journal of Iranian Blood Transfusion Organization* 2005; 2(4),91-98.

28. Rezvan H, Nasiri S, Mousavi K: Inactivation of poliovirus type-I and HSV -I in human coagulation factor VII concentrate by pasteurization. *Arch Irn Med* 2001; 4: 10-13.

29. Nasiri S, Sharifi Z. Evaluation of Viral Inactivation in Suspension Containing 20% Albumin by Pasteurization Method. *Iranian Journal of Virology* 2010; 4: 34-6.

30. Nasiri S, Rezvan H, Mousavi Hosseini K, Roostaei MH. Preparation of highly purified solvent detergent coagulation factor VII and factor IX concentrates from prothrombin complex (PPSB).

Medical Journal of the Islamic Republic of Iran 2001; 15: 103-108.

31. Rezvan H, Nasiri S, Mousavi Hosseini K, Golabi M. A study on the application and efficacy of solvent-detergent (S/D) treatment in the process of purifying factor VII from prothrombin complex. Medical Journal of the Islamic Republic of Iran 2002; 16: 179-82.

32. Burnouf T. Chromatography in plasma fractionation: benefits and future trends. J Chromatogr B Biomed Appl 1995; 664: 3-15.

33. Nasiri S, Heidari M. Application of sodium caprylate as a stabilizer during pasteurization of infusible platelet membrane and evaluation of effectiveness by turbidity assay. Int J Analytical, Pharmaceutical Biomed Sci. 2012; 1: 34-6.

34. Mousavi Hosseini K, Dinarvand R, Pourmokhtar M, Rezvan H, Jalili MA. Pasteurization of IgM-enriched immunoglobulin. Daru 2004; 12(1): 4043.

35. Pourmokhtar M, Dinarvand R, Mousavi Hosseini K, Rezvan H, Jalili MA. Solvent-detergent

treatment of IgM-enriched immunoglobulin. DARU 2003;11(2),47-51.

36. Mousavi Hosseini K, Rezvan H, Motallebi Z, Chabokpey S, Mirbod V. Study of the heat treated human albumin stabilization by caprylate and acetyltryptophanate. Iranian Biomedical Journal 2002;6 (4), 135-140.

37. Johnston A, Adcock W. The Use of Chromatography to Manufacture Purer and Safer Plasma Products. Biotechnology and Genetic Engineering Reviews 2000; 17: 37-70.

38. Valdés R, Ibarra N, Ruibal I, et al. Chromatographic removal combined with heat, acid and chaotropic inactivation of four model viruses. J Biotechnol 2002; 96: 251-8.

39. Brorson K, Norling L, Hamilton E, et al. Current and future approaches to ensure the viral safety of biopharmaceuticals. Dev Biol (Basel) 2004; 118: 17-29.

40. Roberts PL, Lloyd D. Virus inactivation by protein denaturants used in affinity chromatography. Biologicals 2007; 35: 343-7.